Loading data for PSNL — first visit, this takes a few seconds.

アラート

Personalis Inc. (PSNL)

NasdaqGM: PSNL · リアルタイム株価 · USD

18.38

+1.50 (8.89%)

終値時点： Aug 21, 2026, 8:00 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

8.89% (1D)

データがありません

買気配	9.7
時価総額	1.96B
売上高（TTM）	69.67M
純利益（TTM）	-107.18M
	2.29
	-1.09
	n/a
	-19.52
PBR（TTM）	8.31
PSR（TTM）	28.16
決算発表日	Nov 3, 2026

売気配	17.35
出来高	7,980,055
平均出来高（20日）	4,179,569
始値	16.66
前日終値	16.88
当日レンジ	16.62 - 18.89
52週レンジ	4.65 - 18.89
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

PSNLについて

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics t...

[続きを読む]

業種 Diagnostics & Research

セクター Healthcare

IPO日 Jun 20, 2019

従業員数 259

上場取引所 NasdaqGM

ティッカー PSNL

ウェブサイト https://www.personalis.com

企業情報の全文

業績

2025年のPersonalisの売上高は69.65Mで、前年の84.61Mから-17.69%の減少でした。利益は-81.27Mで、-0.02%の減少でした。

財務諸表

決算サプライズ

PersonalisはAug 4, 2026に四半期決算を発表しました：

売上高は $22.36M で、予想を下回りました $0, うち 29.96% の前年比増加にあたります.
EPSは -0.3 で、予想を下回りました -0.02, うち -30.43% の前年比減少.

次回決算発表

Personalis Inc.の決算発表予定日は Nov 3, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

3日前 · Simply Wall St.

Tempus AI (TEM) Stock Looks Fully Valued After Its 55% Jump

Tempus AI stock has surged over the past month, yet the valuation picture is split. The Discounted Cash Flow (DCF) intrinsic value estimate points to shares trading at a roughly 33.1% discount, while ...

3日前 · Simply Wall St.

Tempus AI (TEM) Is Up 39.5% After mRNA Melanoma Trial Win And Personalis Deal - What's Changed

In recent days, investors have reacted to phase 3 INTerpath-001 trial results showing a customized mRNA-based melanoma treatment improved recurrence-free survival, while also focusing on Tempus AI’s p...

3日前 · Simply Wall St.

Has Tempus AI (TEM) Run Too Far Ahead Of Its Valuation Narrative?

Tempus AI (TEM) is back in focus after investors linked a major melanoma trial milestone to its pending US$1.5b acquisition of Personalis Inc, raising fresh questions about how this cancer data deal f...

4日前 · Stocktwits

TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight

BTIG analyst Mark Massaro raised the firm’s price target on Tempus AI to $80 from $70 and kept a Buy rating.

5日前 · 24/7 Wall St.

Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant

Tempus AI wrote a $1.5 billion check for a genomics company most investors had never heard of, and one blockbuster clinical trial announcement just changed everything about how that deal looks.

2ページ中1ページ

Personalis Inc. (PSNL)